Process for the preparation of substituted pyrazole derivatives
A one-pot method for synthesizing 5-ethyl-4-methyl-N-[4-[(2S)morpholin-2-yl]phenyl]-1H-pyrazole-3-carboxamide addresses low yield and high temperature issues, achieving efficient industrial-scale production by optimizing reaction conditions and avoiding intermediate isolation.
Patent Information
- Application Number
- JP2022500840
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2019-09-02
- Filing Date
- 2020-07-09
- Publication Date
- 2024-11-06
- Estimated Expiration
- 2040-07-09
AI Technical Summary
Existing methods for synthesizing 5-ethyl-4-methyl-N-[4-[(2S)morpholin-2-yl]phenyl]-1H-pyrazole-3-carboxamide and its pharmaceutically acceptable salts suffer from low yield and high reaction temperatures, making them unsuitable for industrial-scale production.
A one-pot method involving the reaction of pentan-3-one with dialkyl or diaryl oxalate in the presence of a base, followed by the addition of hydrazine hydrate or a hydrazine salt and an alkali metal hydroxide, with pH adjustment to form 5-ethyl-4-methyl-1H-pyrazole-3-carboxylic acid without intermediate isolation.
The method achieves a higher yield and reduces reaction temperatures, enabling efficient and reproducible industrial-scale synthesis of the compound.
Smart Images

Figure 0007578670000001 
Figure 0007578670000002 
Figure 0007578670000003
Abstract
Description
[Technical field]
[0001] The present invention relates to a novel process for preparing 5-ethyl-4-methyl-N-[4-[(2S)morpholin-2-yl]phenyl]-1H-pyrazole-3-carboxamide (Formula I) or a pharma- ceutically acceptable salt thereof. [ka] [Background technology]
[0002] The compounds of formula I are TAAR1 inhibitors useful for treating various diseases and disorders, such as depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder (ADHD), stress-related disorders, schizophrenia, Parkinson's disease, Alzheimer's disease, epilepsy, migraine, hypertension, drug abuse, addiction, eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy expenditure and assimilation, disorders and dysfunction of temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders (PCT Application WO2017157873).
[0003] WO2017157873 discloses a process for preparing a compound of formula I, comprising reacting 5-ethyl-4-methyl-1H-pyrazole-3-carboxylic acid (1) with (2S)-2-(4-aminophenyl)morpholine-4-carboxylate (2) to form tert-butyl (2S)-2-[4-[(5-ethyl-4-methyl-1H-pyrazole-3-carbonyl)amino]phenyl]morpholine-4-carboxylate (3). [ka]
[0004] (2S)-2-(4-aminophenyl)morpholine-4-carboxylate (2) can be obtained, for example, as described in PCT application WO2015086495.
[0005] 5-Ethyl-4-methyl-1H-pyrazole-3-carboxylic acid (1) can be obtained, for example, as described in Philip J. Skinner et al., Bioorg. Med. Chem. Lett. 2007, 17, 5620-5623.
[0006] For marketing products, drugs need to be manufactured in large quantities and in accordance with Good Manufacturing Practice ("GMP") standards, therefore a high-yielding, inexpensive and reproducible synthesis is paramount.
[0007] The synthesis of 5-ethyl-4-methyl-1H-pyrazole-3-carboxylic acid (1) described in Skinner et al. has several drawbacks, such as low yields and high reaction temperatures, which ultimately affect the industrial-scale synthesis of the compound of formula I by the procedure described in WO2017157873.
[0008] Therefore, there is a need for new processes for preparing the compound of formula (I) or a pharma- ceutically acceptable salt thereof. Summary of the Invention
[0009] In a first aspect, the present invention provides a process for preparing 5-ethyl-4-methyl-N-[4-[(2S)morpholin-2-yl]phenyl]-1H-pyrazole-3-carboxamide (Formula I) or a pharma- ceutically acceptable salt thereof, comprising the steps of: [ka] a) pentan-3-one (4), [ka] In the presence of a base, dialkyl or diaryl oxalate 5, where R is C1-C6-alkyl or C6-C 14 -aryl); [ka] b) adding (i) hydrazine hydrate in the presence of an acid such as acetic acid or hydrochloric acid, or (ii) a hydrazine salt such as hydrazine acetate or hydrazine hydrochloride to the reaction mixture obtained in step a); c) adding an aqueous solution of an alkali metal hydroxide to the mixture obtained in step b); and d) adjusting the pH of the mixture obtained in step c) to a pH below 6 by adding an acid; to form 5-ethyl-4-methyl-1H-pyrazole-3-carboxylic acid (1), [ka] Provided is a process wherein steps a) to d) are carried out without isolating any intermediates. In a further aspect, the present invention provides a process for producing 5-ethyl-4-methyl-1H-pyrazole-3-carboxylic acid (1), comprising the steps of: [ka] a) pentan-3-one (4), [ka] In the presence of a base, dialkyl or diaryl oxalate 5, where R is C1-C6-alkyl or C6-C 14 -aryl); [ka] b) adding (i) hydrazine hydrate in the presence of an acid such as acetic acid or hydrochloric acid, or (ii) a hydrazine salt such as hydrazine acetate or hydrazine hydrochloride to the reaction mixture obtained in step a); c) adding an aqueous solution of an alkali metal hydroxide to the mixture obtained in step b); and d) adjusting the pH of the mixture obtained in step c) to a pH below 6 by adding an acid; to form the 5-ethyl-4-methyl-1H-pyrazole-3-carboxylic acid (1), Provided is a process wherein steps a) to d) are carried out without isolating any intermediates.
[0010] In a further aspect, the present invention provides the use of the one-pot process for the preparation of 5-ethyl-4-methyl-1H-pyrazole-3-carboxylic acid (1) as described herein for the preparation of 5-ethyl-4-methyl-N-[4-[(2S)morpholin-2-yl]phenyl]-1H-pyrazole-3-carboxamide (Formula I) or a pharma-ceutically acceptable salt thereof.
[0011] In a further aspect, the present invention provides 5-ethyl-4-methyl-N-[4-[(2S)morpholin-2-yl]phenyl]-1H-pyrazole-3-carboxamide (Formula I), or a pharma- ceutically acceptable salt thereof, obtainable by the methods described herein. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0012] definition It should be understood that features, integers, properties, compounds, chemical moieties or groups described in connection with a particular aspect, embodiment or example of the invention are applicable to any other aspect, embodiment or example described herein, except where incompatible. All of the features disclosed herein (including any accompanying claims, and abstract), and / or all of the steps of any method or process so disclosed, may be combined in any combination, except combinations in which at least some of such features and / or steps are mutually exclusive. The invention is not limited to the details of any of the foregoing embodiments. The invention extends to any novel or any novel combination of features disclosed herein (including any accompanying claims, and abstract), or any novel or any novel combination of steps of any method or process so disclosed.
[0013] The term "alkyl" refers to a monovalent, linear or branched, saturated hydrocarbon radical of one to six carbon atoms, e.g., 1, 2, 3, 4, 5, or 6 carbon atoms ("C 1~6 In other embodiments, an alkyl group contains 1 to 3 carbon atoms, such as 1, 2, or 3 carbon atoms. Some non-limiting examples of alkyl include methyl, ethyl, propyl, 2-propyl (isopropyl), n-butyl, iso-butyl, sec-butyl, tert-butyl, and 2,2-dimethylpropyl. A particularly preferred, but non-limiting example of alkyl is ethyl.
[0014] The term "aryl" refers to an alkyl group having 6 to 14 total ring members ("C 6~14 "-aryl"), preferably a monocyclic, bicyclic, or tricyclic carbocyclic ring system having 6 to 12 ring members, more preferably 6 to 10 ring members, in which at least one ring of the system is aromatic. A preferred, but non-limiting example of an aryl is phenyl.
[0015] The term "base" refers to a base suitable for use in Claisen condensation, such as an alkoxide, hydride, or dialkyl azanide. Particular examples of bases are sodium or potassium methoxide, sodium or potassium ethoxide, sodium or potassium tert-butoxide, lithium diisopropylamide (LDA), and sodium or potassium hydride. Examples of preferred bases are sodium ethoxide, sodium methoxide, and potassium tert-butoxide. An example of a particularly preferred base is sodium methoxide.
[0016] The term "acid" refers to a compound that has at least one acidic proton. Specific non-limiting examples of acids are hydrochloric acid and acetic acid. Manufacturing method The present invention provides a process for preparing 5-ethyl-4-methyl-N-[4-[(2S)morpholin-2-yl]phenyl]-1H-pyrazole-3-carboxamide (Formula I) or a pharma- ceutically acceptable salt thereof, comprising the steps of: [ka] 5-Ethyl-4-methyl-1H-pyrazole-3-carboxylic acid (1), [ka] The present invention relates to methods, including a one-pot method for preparing as outlined in Scheme 1. [ka]
[0017] Scheme 1 According to the one-pot method of the present invention, pentan-3-one (4) is reacted with a dialkyl or diaryl oxalate 5 (wherein R is C1-C6-alkyl or C6-C 14 Claisen condensation with 5-ethyl-4-methyl-1H-pyrazole-3-carboxylic acid (1), preferably with diethyl oxalate, in the presence of a base such as an alkali metal alkoxide, in particular sodium ethoxide, gives intermediate 6, which is reacted in the presence of an acid with hydrazine, more particularly with a hydrazine salt, such as hydrazine hydrochloride or hydrazine acetate (also formed in situ from the individual components), to give carboxylic acid ester 7. The carboxylic acid ester 7 is then saponified by adding an aqueous solution of an alkali metal hydroxide, such as LiOH, NaOH or KOH, in particular NaOH, directly to the reaction mixture obtained from the cyclization step. 5-Ethyl-4-methyl-1H-pyrazole-3-carboxylic acid (1) is finally obtained by acidifying the reaction mixture (to pH less than 7, in particular less than pH 3, preferably pH=2.0-2.5), for example by adding aqueous hydrochloric acid.
[0018] One surprising advantage of the one-pot process for preparing 5-ethyl-4-methyl-1H-pyrazole-3-carboxylic acid (1) described herein is that it results in a higher yield (i.e., 75% vs. 26%) than the process disclosed, for example, in Philip J. Skinner et al., Bioorg. Med. Chem. Lett. 2007, 17, 5620-5623. In a first aspect, the present invention provides a process for preparing 5-ethyl-4-methyl-N-[4-[(2S)morpholin-2-yl]phenyl]-1H-pyrazole-3-carboxamide (Formula I) or a pharma- ceutically acceptable salt thereof, comprising the steps of: [ka] a) pentan-3-one (4), [ka] In the presence of a base, dialkyl or diaryl oxalate 5, where R is C1-C6-alkyl or C6-C 14 -aryl); [ka] b) adding (i) hydrazine hydrate in the presence of an acid such as acetic acid or hydrochloric acid, or (ii) a hydrazine salt such as hydrazine acetate or hydrazine hydrochloride to the reaction mixture obtained in step a); c) adding an aqueous solution of an alkali metal hydroxide to the mixture obtained in step b); and d) adjusting the pH of the mixture obtained in step c) to a pH below 6 by adding an acid; to form 5-ethyl-4-methyl-1H-pyrazole-3-carboxylic acid (1), [ka] Provided is a process wherein steps a) to d) are carried out without isolating any intermediates. In a further aspect, the present invention provides a process for producing 5-ethyl-4-methyl-1H-pyrazole-3-carboxylic acid (1), comprising the steps of: [ka] a) pentan-3-one (4), [ka] In the presence of a base, dialkyl or diaryl oxalate 5, where R is C1-C6-alkyl or C6-C 14 -aryl); [ka] b) adding (i) hydrazine hydrate in the presence of an acid such as acetic acid or hydrochloric acid, or (ii) a hydrazine salt such as hydrazine acetate or hydrazine hydrochloride to the reaction mixture obtained in step a); c) adding an aqueous solution of an alkali metal hydroxide to the mixture obtained in step b); and d) adjusting the pH of the mixture obtained in step c) to a pH below 6 by adding an acid; to form the 5-ethyl-4-methyl-1H-pyrazole-3-carboxylic acid (1), Provided is a process wherein steps a) to d) are carried out without isolating any intermediates.
[0019] In one embodiment, more than one equivalent of pentan-3-one (4) relative to the dialkyl or diaryl oxalate 5 is used in step a).
[0020] In a preferred embodiment, about 1 equivalent to about 2 equivalents of pentan-3-one (4) relative to the dialkyl or diaryl oxalate 5 are used in step a).
[0021] In a particularly preferred embodiment, about 1 equivalent to about 1.5 equivalents, for example about 1.2 equivalents, of pentan-3-one (4) relative to the dialkyl or diaryl oxalate 5 are used in step a).
[0022] In one embodiment, the oxalate 5 in step a) of the process of the invention is a dialkyl oxalate, where R is C1-C6-alkyl.
[0023] In one embodiment, the oxalate 5 in step a) of the process of the invention is diethyl oxalate.
[0024] In one embodiment the base in step a) of the process of the invention is an alkali metal alkoxide.
[0025] In one embodiment the base in step a) of the process of the invention is sodium ethoxide.
[0026] In one embodiment, about 1 equivalent to about 2 equivalents of base relative to dialkyl or diaryl oxalate 5 are used in step a).
[0027] In a preferred embodiment, about 1 equivalent to about 1.5 equivalents of base relative to the dialkyl or diaryl oxalate 5 are used in step a).
[0028] In a particularly preferred embodiment, about 1 equivalent to about 1.1 equivalents of base relative to the dialkyl or diaryl oxalate 5 are used in step a).
[0029] In one embodiment, step a) is carried out at a temperature below 75°C, for example between about 0°C and about 25°C.
[0030] In a preferred embodiment, step a) is carried out at a temperature between about 0°C and about 10°C.
[0031] In a particularly preferred embodiment, step a) is carried out at between about 0°C and about 5°C.
[0032] In one embodiment, in step b) of the method of the present invention, a hydrazine salt selected from the group consisting of hydrazine hydrochloride (N2H4·HCl) and hydrazine acetate (N2H4·CH3COOH) is used as is or formed in situ, respectively.
[0033] In a preferred embodiment, in step b) of the process of the invention, hydrazine acetate (N2H4·CH3COOH) is used as is or formed in situ.
[0034] In one embodiment, about 0.95 equivalents to about 1.5 equivalents of hydrazine or hydrazine salt relative to dialkyl or diaryl oxalate 5 are used in step b).
[0035] In a preferred embodiment, about 0.95 equivalents to about 1.1 equivalents of hydrazine or a hydrazine salt relative to the dialkyl or diaryl oxalate 5 are used in step b).
[0036] In a particularly preferred embodiment, less than 1 equivalent of hydrazine or hydrazine salt relative to diester 5, such as about 0.95 equivalents, is used in step b).
[0037] In some cases, it has been found that the use of less than one equivalent of hydrazine relative to the diester 5 in step b) beneficially reduces the level of contamination of the desired product in 5-ethyl-4-methyl-1H-pyrazole-3-carboxylic acid (1) with the hydrazide derivative.
[0038] In one embodiment, step b) is carried out at less than about 5°C.
[0039] In a preferred embodiment, step b) is carried out at below about 0°C.
[0040] In a particularly preferred embodiment, step b) is carried out at a temperature between about -15°C and about 0°C.
[0041] In one embodiment of the process of the present invention, the alkali metal hydroxide in step c) is LiOH, KOH or NaOH.
[0042] In a preferred embodiment of the process of the present invention, the alkali metal hydroxide in step c) is NaOH.
[0043] In one embodiment, about 2 equivalents to about 4 equivalents of alkali metal hydroxide relative to the dialkyl or diaryl oxalate 5 are used in step c).
[0044] In a preferred embodiment, about 2 equivalents to about 3 equivalents of an alkali metal hydroxide relative to the dialkyl or diaryl oxalate 5 are used in step c).
[0045] In a particularly preferred embodiment, about 2.5 equivalents to about 2.9 equivalents, for example about 2.85 equivalents, of an alkali metal hydroxide relative to the dialkyl or diaryl oxalate 5 are used in step c).
[0046] In one embodiment, step c) is carried out at a temperature below 30°C, for example between about 0°C and about 30°C.
[0047] In a preferred embodiment, step c) is carried out at a temperature between about 0°C and about 20°C.
[0048] In a particularly preferred embodiment, step c) is carried out at a temperature between about 0°C and about 15°C.
[0049] In one embodiment, the mixture obtained in step c) is stirred at an elevated temperature (eg, about 40° C. to about 50° C.) for an extended period of time (eg, about 10 to about 20 hours).
[0050] In one embodiment, step c) comprises adding an aqueous solution of an alkali metal hydroxide to the mixture obtained in step b) until the pH is about 12.5 or higher, such as about 14.
[0051] In one embodiment of the method of the present invention, in step d), the pH of the mixture obtained in step c) is adjusted to about pH 1.5 to about pH 5.
[0052] In a preferred embodiment of the method of the present invention, in step d), the pH of the mixture obtained in step c) is adjusted to between about pH 1.5 and about pH 3.
[0053] In a particularly preferred embodiment of the method of the present invention, in step d), the pH of the mixture obtained in step c) is adjusted to between about pH 2.0 and about pH 2.5.
[0054] In one embodiment of the process of the invention, the acid added in step d) is hydrochloric acid.
[0055] In one embodiment, the acid in step d) is added at about 0°C to about 60°C.
[0056] In a preferred embodiment, the acid in step d) is added at about 40°C to about 50°C.
[0057] In a particularly preferred embodiment, the acid in step d) is added at about 45°C. In one embodiment, the present invention relates to a process for preparing 5-ethyl-4-methyl-N-[4-[(2S)morpholin-2-yl]phenyl]-1H-pyrazole-3-carboxamide (Formula I) or a pharma- ceutically acceptable salt thereof, or a process for preparing 5-ethyl-4-methyl-1H-pyrazole-3-carboxylic acid (1) as described herein, comprising: a) pentan-3-one (4, greater than 1 equivalent relative to dialkyl oxalate 5), [ka] reacting with dialkyl oxalate 5, where R is C1-C6-alkyl (1.00 equivalent) in the presence of a base (about 1 equivalent to about 2 equivalents) at a temperature below 75° C., for example between about 0° C. and about 25° C.; [ka] b) adding about 0.95 equivalents to about 1.5 equivalents relative to 5 of (i) hydrazine hydrate in the presence of an acid such as acetic acid or hydrochloric acid, or (ii) a hydrazine salt such as hydrazine acetate or hydrazine hydrochloride to the reaction mixture obtained in step a) at less than about 5° C.; c) adding an aqueous solution of an alkali metal hydroxide (about 2 equivalents to about 4 equivalents relative to 5) to the mixture obtained in step b) at a temperature of less than about 30° C.; and d) adjusting the pH of the mixture obtained in step c) to about pH 1.5 to about pH 5 by adding an acid at about 0° C. to about 60° C.; to form 5-ethyl-4-methyl-1H-pyrazole-3-carboxylic acid (1).
[0058] In a preferred embodiment, the present invention relates to a process for preparing 5-ethyl-4-methyl-N-[4-[(2S)morpholin-2-yl]phenyl]-1H-pyrazole-3-carboxamide (Formula I) or a pharma- ceutically acceptable salt thereof, or a process for preparing 5-ethyl-4-methyl-1H-pyrazole-3-carboxylic acid (1) as described herein, comprising the steps of: a) pentan-3-one (about 1 equivalent to about 2 equivalents relative to 4 and 5), [ka] reacting with dialkyl oxalate 5, where R is C1-C6-alkyl (1.00 equivalents), in the presence of a base (about 1 equivalent to about 1.5 equivalents) at between about 0° C. and about 10° C., where the base is an alkali metal alkoxide; [ka] b) adding about 0.95 equivalents to about 1.1 equivalents of a hydrazine salt relative to 5 to the reaction mixture obtained in step a) while maintaining the temperature below about 0° C. (wherein the hydrazine salt is hydrazine hydrochloride (N2H4·HCl) or hydrazine acetate (N2H4·CH3COOH) either neat or formed in situ); c) adding an aqueous solution of an alkali metal hydroxide (about 2 equivalents to about 3 equivalents relative to 5) to the mixture obtained in step b) at a temperature of less than about 20° C., where the alkali metal hydroxide is LiOH, KOH, or NaOH; and d) adjusting the pH of the mixture obtained in step c) to between about pH 1.5 and about pH 3 by adding an acid at about 0° C. to about 60° C.; to form 5-ethyl-4-methyl-1H-pyrazole-3-carboxylic acid (1). In a particularly preferred embodiment, the present invention relates to a process for preparing 5-ethyl-4-methyl-N-[4-[(2S)morpholin-2-yl]phenyl]-1H-pyrazole-3-carboxamide (Formula I) or a pharma- ceutically acceptable salt thereof, or a process for preparing 5-ethyl-4-methyl-1H-pyrazole-3-carboxylic acid (1) as described herein, comprising the steps of: a) pentan-3-one (about 1 equivalent to about 1.5 equivalents relative to 4 and 5, for example about 1.2 equivalents), [ka] reacting with diethyl oxalate 5a (1.00 equivalent) in the presence of sodium ethoxide or sodium methoxide, preferably sodium ethoxide (about 1.0 equivalent to about 1.1 equivalent) at about 0° C. to about 5° C.; [ka] b) adding less than 1 equivalent relative to 5, for example about 0.95 equivalents, of hydrazine acetate (N2H4·CH3COOH) formed neat or in situ, to the reaction mixture obtained in step a) while maintaining the temperature below about 0° C.; c) adding an aqueous solution of NaOH (about 2.5 equivalents to about 2.9 equivalents relative to 5, e.g., about 2.85 equivalents) to the mixture obtained in step b) while maintaining the temperature between about 0° C. and about 15° C.; and d) adjusting the pH of the mixture obtained in step c) to between about pH 2.0 and about pH 2.5 by adding hydrochloric acid at about 40° C. to about 50° C.; to form 5-ethyl-4-methyl-1H-pyrazole-3-carboxylic acid (1).
[0059] In a further aspect, the present invention provides the use of the one-pot process for preparing 5-ethyl-4-methyl-1H-pyrazole-3-carboxylic acid (1) as described herein for the preparation of 5-ethyl-4-methyl-N-[4-[(2S)morpholin-2-yl]phenyl]-1H-pyrazole-3-carboxamide (Formula I) or a pharma- ceutically acceptable salt thereof.
[0060] In a further aspect, the present invention provides 5-ethyl-4-methyl-N-[4-[(2S)morpholin-2-yl]phenyl]-1H-pyrazole-3-carboxamide (Formula I), or a pharma- ceutically acceptable salt thereof, obtainable by the methods described herein. Working Example
[0061] The present invention will be more fully understood by reference to the following examples, which should not, however, be construed as limiting the scope of the claims to the examples.
[0062] Unless otherwise stated, all reactions were carried out under a protective gas atmosphere (e.g., argon or nitrogen).
[0063] Example 1 5-Ethyl-4-methyl-1H-pyrazole-3-carboxylic acid (1) 3-Pentanone (93.0 g, 1.08 mol, 1.20 equiv.) was added to a pre-cooled (-5 to 0 °C) solution of diethyl oxalate (132 g, 903 mmol, 1.00 equiv.) in 20% ethanolic sodium ethoxide (338 g, 994 mmol, 1.10 equiv.). The line was rinsed with ethanol (50 mL). After stirring at this temperature for 2 h, the reaction mixture was cooled to approximately -15 °C and a cold (approximately 0 °C) solution of 40% aqueous hydrazine (118 g, 948 mmol, 1.05 equiv.) in acetic acid (59.7 g, 994 mmol, 1.10 equiv.) was added dropwise over 2 h, ensuring that the reaction temperature did not exceed 0 °C. Stirring was continued for 1 h. 50% aqueous sodium hydroxide (205 g, 2.57 mol, 2.85 equiv.) was added while maintaining the internal temperature between 0 and 15 °C. The solution was stirred at 20 ± 5 °C for 2 h and then at 40 ± 5 °C for 16 h to form a clear solution. Concentrated (37%) aqueous hydrochloric acid (350 mL, 3.68 mol, 4.07 equiv.) was added at 45 ± 5 °C and the resulting suspension was stirred for 0.5 h. Most of the organic solvent (approximately 475 mL of ethanol) was removed under reduced pressure at 45 ± 5 °C. Water (475 mL) was added and the mixture was stirred at 45 ± 5 °C for 1 h. The precipitate was filtered and washed with water (100 mL). The crude product was dissolved in water (650 mL) and the pH was adjusted to 7.5-8 by the addition of 50% aqueous NaOH (65 g). The mixture was stirred at room temperature for 1 h, after which celite (25 g) was added and bound insoluble material was removed by filtration. The filter cake was rinsed with water (150 mL) and the collected filtrate was warmed and maintained at 40-45°C while acidifying to pH 2-2.5 by addition of 37% aqueous HCl (82 mL). The resulting suspension was stirred at 40-45°C for 1 h, filtered and the residue washed with water (200 mL). The product was once again slurried in water (650 mL) at 35-40°C for 1 h to remove the last traces of residual oxalic acid by dissolution. After filtration, washing with water (200 mL) and drying (below 45°C under vacuum), the title compound was obtained as an off-white solid (108 g, 78% yield).
[0064] C7H10 Elemental analysis for N2O2 (154.17). Calculated: C: 54.54%, H: 6.54%, N: 18.17%; Found: C: 54.73, H: 6.53, N: 18.31; Water content (Karl Fisher titration): less than 0.1%.
Claims
1. A process for producing 5-ethyl-4-methyl-1H-pyrazole-3-carboxylic acid (1), comprising the steps of: 【Chemistry 1】 a) pentan-3-one (4), 【Chemistry 2】 In the presence of a base, a dialkyl or diaryl oxalate 5, 1 ~C 6 -Alkyl or C 6 ~C 14 -aryl; 【Chemistry 3】 b) adding (i) hydrazine hydrate in the presence of an acid, or (ii) a hydrazine salt to the reaction mixture obtained in step a); c) adding an aqueous solution of an alkali metal hydroxide to the mixture obtained in step b); and d) adjusting the pH of the mixture obtained in step c) to a pH below 6 by adding an acid; to form the 5-ethyl-4-methyl-1H-pyrazole-3-carboxylic acid (1); A process wherein steps a) to d) are carried out without isolating any intermediates.
2. In step a), the oxalate 5 is a dialkyl oxalate (wherein R is C 1 ~C 6 -alkyl.
3. 2. The method of claim 1, wherein the oxalate 5 in step a) is diethyl oxalate.
4. 4. The process according to claim 1, wherein the base in step a) is sodium ethoxide.
5. 5. The method according to any one of claims 1 to 4, wherein step a) is carried out between 0°C and 25°C.
6. The method according to claim 1, wherein in step b) (i) an acid selected from the group consisting of hydrochloric acid and acetic acid, or (ii) a hydrazine salt selected from the group consisting of hydrazine hydrochloride and hydrazine acetate, is used.
7. In step b), hydrazine hydrochloride (N 2 H 4 HCl) and hydrazine acetate (N 2 H 4 ・CH 3 7. The method according to claim 1, wherein a hydrazine salt selected from the group consisting of: hydrazine salts of the formula (I) and (II) and (III) is used as such or formed in situ, respectively.
8. 8. The process according to any one of claims 1 to 7, wherein step b) is carried out between 0°C and -15°C.
9. 9. The method according to claim 1, wherein the alkali metal hydroxide in step c) is LiOH, KOH or NaOH.
10. 10. The method according to claim 1, wherein the alkali metal hydroxide in step c) is NaOH.
11. 11. The method according to any one of claims 1 to 10, wherein step c) is carried out between 0°C and 15°C.
12. 12. The method according to any one of claims 1 to 11, wherein in step d) the pH of the mixture obtained in step c) is adjusted to a pH below 3.
13. 13. The process according to any one of claims 1 to 12, wherein the acid added in step d) is hydrochloric acid.
14. The preparation of 5-ethyl-4-methyl-N-[4-[(2S)morpholin-2-yl]phenyl]-1H-pyrazole-3-carboxamide (formula I) using the method according to any one of claims 1 to 13. 【Chemistry 4】 or a pharma- ceutically acceptable salt thereof.
Citation Information
Patent Citations
5-Ethyl-4-methyl-pyrazole-3-carboxamide derivatives with TAAR agonist activity
JP2019512469A
